Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797784 | 0.93 | ADORA3 (0.63) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL19991774 | 0.89 | ADORA3 (0.64) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL17825933 | 0.89 | ADORA3 (0.77) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL638672 | 0.89 | ADORA3 (0.77) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL638673 | 0.89 | ADORA3 (0.77) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL17824381 | 0.89 | ADORA3 (0.77) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL1798064 | 0.88 | ADORA3 (0.68) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL25170475 | 0.88 | ADORA3 (0.75) | ADORA3ADORA2AADORA1ADORA2BTP53 | |
| SCHEMBL1798060 | 0.87 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL14689154 | 0.85 | DNPH1 (0.79) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1848718-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006084281-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | ADORA3 1669/4885ADORA2A 1750/4885ADORA1 857/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | ADORA3 3584/4885ADORA2A 3026/4885ADORA1 2055/4885 |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | ADORA3 24/4885ADORA2A 185/4885ADORA1 232/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | ADORA3 3584/4885ADORA2A 3026/4885ADORA1 2055/4885 |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | ADORA3 24/4885ADORA2A 185/4885ADORA1 232/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | ADORA3 3584/4885ADORA2A 3026/4885ADORA1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.